The expanded approval of two HPV tests allows the patient to collect a vaginal sample themselves in a health care setting, rather than a health provider collecting a sample during a pelvic exam. The availability of a self-collection option in health care settings could help widen access to cervical cancer screening. https://go.nih.gov/Sh0T2dn Media Description: This image shows a COS cell transfected with the HPV-16 E5 oncoprotein. Fluorescence red color represents E5, green represents karypherin-beta-3, and co-localization of both proteins is shown in yellow. The E5-transfected cell (green) is demonstrated on top of the image. Circular dark object in the middle is a cell nucleus.
National Cancer Institute (NCI)
政府管理
Bethesda，MD 324,957 位关注者
The National Cancer Institute, part of the National Institutes of Health, is the lead federal agency for cancer research
关于我们
The National Cancer Institute (NCI), part of the National Institutes of Health, is the lead federal agency for cancer research. For more information about NCI, visit us at www.cancer.gov. Privacy policy: https://www.cancer.gov/policies/privacy-security Engagement ≠ endorsement
- 网站
-
https://www.cancer.gov
National Cancer Institute (NCI)的外部链接
- 所属行业
- 政府管理
- 规模
- 1,001-5,000 人
- 总部
- Bethesda，MD
- 类型
- 政府机构
- 领域
- cancer、cancer research、cancer training、cancer research grants、cancer resources、cancer information和cancer research funding
地点
National Cancer Institute (NCI)员工
动态
-
What is a principal investigator (PI)? This is the person in charge of a clinical trial or a scientific research grant. The principal investigator prepares and carries out the clinical trial protocol (plan for the study) or research paid for by the grant. https://go.nih.gov/KiZkWGO
-
-
Inside Cancer Careers is a podcast that explores and illuminates the exciting world of cancer research training to bring a new generation of investigators into the field. The podcast provides insights from established investigators and uncovers emerging trends in cancer research. Check it out! https://go.nih.gov/y4h2mev
-
-
FDA recently approved the first blood test for the primary screening of people at average risk of colorectal cancer. Where does the test, called Shield, fit in with other screening options for the disease, including colonoscopy and stool tests? https://go.nih.gov/1AA7pu0
-
-
For people with advanced kidney cancer, an injectable form of nivolumab (Opdivo) is a suitable alternative to the original intravenous form, early results from a clinical trial have shown. Experts say the injectable form makes the treatment quicker and easier for patients to receive. https://go.nih.gov/E7TjMVT Image Description: Color-coded mouse kidney cells
-
-
Mutations in molecular signaling pathways often result in abnormal cell motility, or movement in the body. Cell motility is driven by cytoskeleton proteins that help cancer cells invade other tissues (metastasis). This 2016 image shows cytoskeletal proteins actin (in green) and tubulin (in red) in HeLa cervical cancer cells.
-
-
Following positive results from a large clinical trial, the immunotherapy drug blinatumomab (Blincyto) is expected to become part of the standard initial treatment for many children with B-cell acute lymphoblastic leukemia, the most common form of childhood cancer. https://go.nih.gov/zRhj89x
-
-
A new NCI-supported clinical trial is testing a drug in people with tumors of the brain or spinal cord. Some participants will have tumors with changes in the MYC gene or the MYCN gene. Learn more about the drug (PLX038) and the study: https://go.nih.gov/MdSQh2I Image Description: Microscopy images of four different MYCN amplified ependymomas. The bright spots indicate extra copies of the MYCN gene. Credit: Raffeld et al. Acta Neuropathologica Communications. 2020 Dec; 8(1):1-1.
-
-
People with central nervous system tumors are usually cared for by a team of health care professionals who have special training. NCI offers information on diagnosis, grading, tumor types, genetics, and the specialists who treat people who have these tumors. https://go.nih.gov/VuwKUvY
-
-
Although TP53 mutations help drive the growth of most cancers, there are no FDA-approved therapies that target altered p53 proteins. Now a drug combination has shown promise in mice and is being tested in a clinical trial. https://go.nih.gov/3vKdrxj
-